Acute and chronic kidney diseases are common and now recognized as a public health problem in developed and developing nations. Acute kidney injury (AKI) occurs in up to 10-20% of hospitalized patients and chronic kidney disease (CKD) is present in 10-15% of adults in the general population. 1 Both conditions are more common in the elderly and in patients with other chronic diseases, and are associated with an increased risk of subsequent chronic kidney failure, cardiovascular disease, and mortality.
Kidney diseases may have many effects on pharmacokinetics and pharmacodynamics, and the level of kidney function is a key consideration in the development, approval, and use of drugs. Glomerular filtration rate (GFR) is generally considered the best overall index of kidney function in health and disease, and, in this review, we will limit our scope to the assessment of GFR in adults (not including patients treated by dialysis or hemofiltration). However, the kidney has other functions in addition to glomerular filtration, including other excretory functions (tubular reabsorption and secretion), and endocrine and metabolic functions. Another article in this series will discuss markers of other kidney functions.
There has been substantial progress in the past 20 years in the use of GFR estimating equations to define and classify acute and CKDs, with a number of new GFR estimating equations using creatinine, cystatin C, and the combination. 2, 3 In principle, use of a single equation for each filtration marker (or combination) for detection, evaluation, and management of kidney disease and drug dosing would facilitate clinical practice. In a previous debate in Clinical Pharmacology & Therapeutics, 4 we emphasized the need to change from rigid adherence to the use of the CockcroftGault equation for use in drug development and drug dosing because of changes in serum creatinine assays since it was developed, and because it is less accurate than the newer GFR estimating equations, which are more widely used in clinical practice (Modification of Diet in Renal Disease (MDRD) study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations). This article will review the principles for assessment of GFR, will provide historical perspective and updates regarding the use of GFR estimating equations, including assay methods for creatinine and cystatin C, performance of estimating equations, and recommendations by clinical practice guideline groups and regulatory agencies ( Figure 1 ). Throughout this article, we will use material from our recent reviews. [5] [6] [7] [8] [9] [10] 
GLOMERULAR FILTRATION
Glomerular filtration is the physiologic process of creating an ultrafiltrate of blood as it flows through the glomerular capillaries. In principle, the GFR is the product of the number of nephrons times the average single-nephron glomerular filtration rate (SNGFR). Determinants of SNGFR include hemodynamic factors within the glomerular capillary network and the properties of the capillary wall.
Based on a large body of evidence, mean GFR in healthy young adult white individuals is 125 mL/min/1.73 m 2 , with a wide range. Indexing GFR to body surface area (BSA) reduces variation among healthy individuals and allows comparisons to normative values, although nonindexed GFR is preferable for drug dosing. There is some evidence that the normal level of GFR varies among ethnic groups. GFR is affected by numerous physiologic and pathologic conditions causing intra-individual and interindividual variability, including time of day, dietary protein intake, exercise, age, pregnancy, body composition, hyperglycemia, use of antihypertensive drugs, surfeit or deficit of extracellular fluid, and acute and CKD. Within a healthy individual, after controlling for dietary intake and diurnal variation, GFR is relatively constant over short intervals of time, but varies considerably among people, even after adjustment for the known variables.
Reductions in GFR may result from a decline in the nephron number or in the SNGFR from physiologic or hemodynamic alterations. An increase in SNGFR caused by increased glomerular capillary pressure or glomerular hypertrophy can compensate for a decrease in nephron number; therefore, the level of GFR may not reflect the loss of nephrons. As a result, there may be substantial kidney damage in AKI or CKD before GFR decreases.
GFR assessment
The GFR cannot be measured directly in humans. Instead, it is assessed from clearance measurements or serum levels of filtration markers, exogenous or endogenous solutes that are mainly eliminated by glomerular filtration (Figure 2) . 5 Both measured GFR (mGFR) and estimated GFR (eGFR) are associated with systematic and random error (bias and imprecision, respectively) in their determination, and, thus, may differ from the "true GFR."
The classic method for GFR measurement described by Homer Smith is the urinary clearance of inulin and remains the reference (gold standard) against which other clearance methods and filtration markers are evaluated. 6 However, this technique is cumbersome in practice. Therefore, many alternative clearance methods and filtration markers are used in clinical centers and as a research tool. The development of methods to estimate the GFR from serum levels of endogenous filtration markers has simplified GFR assessment without requiring administration of exogenous filtration markers and without performing clearance measurements. The principles of GFR estimation are similar in adults and children, but, in this article, we only discuss GFR estimating equations developed in adults.
GFR MEASUREMENT USING CLEARANCE OF FILTRATION MARKERS Concept of clearance
Clearance of a solute is defined as the volume of plasma cleared of a marker by excretion per unit of time. The clearance (CL) of substance is defined as the amount of the solute eliminated from the plasma divided by the average plasma concentration of the solute during the interval of elimination, with CL expressed in units of volume per time. 5 Clearance does not represent an actual volume; rather, it is a virtual volume of plasma that is completely cleared of the solute per unit of time. The value for clearance is related to the efficiency of elimination: the greater the efficiency of elimination, the higher the clearance. Clearance of the solute is the sum of the urinary clearance and extrarenal clearance by gut, biliary, and other routes. By convention, we refer to concentration in plasma when discussing physiological principles and serum when discussing clinical measures. In practice, laboratory measurements of filtration markers are similar in plasma and serum, and are generally referred to as serum concentrations.
Plasma clearance
Plasma clearance refers to the elimination of the marker from plasma without knowledge of its route of elimination (Figure 2a) . Plasma clearance can be measured after bolus intravenous administration of an exogenous filtration marker, where A is the amount of the marker administered, and P is the average plasma concentration, computed from the area under the curve of plasma concentration vs. time. The decline in plasma levels is Figure 2 Methods to assess clearance (CL) and glomerular filtration rate (GFR). (a) Plasma clearance. CL (mL/min) can be computed from the amount (denoted A) of solute infused into plasma per unit of time (mg/min) divided by average plasma concentration (P; mg/mL) during the interval of observation and can by conceptualized as the virtual volume of plasma "cleared" of a solute per unit time. Plasma clearance (CL P ) is the sum of clearance by all mechanisms, generally categorized as urinary clearance (CL U ) and extrarenal clearance (CL E ) by gut and biliary elimination. (b) Urinary clearance. Urinary excretion (UV; mg/min) is the sum of the filtered load (the product of GFR 3 plasma concentration 3 sieving coefficient) 1 tubular secretion (TS; mg/min) -tubular reabsorption (TR; mg/min). The CL U is measured as the amount of marker excreted in urine (U 3 V) per unit time divided by plasma concentration (P) of the marker during the urine collection period. (c) Estimation of GFR from plasma concentration of endogenous filtration markers. In the steady state, a constant plasma concentration (P; mg/mL) of the filtration marker is maintained because generation (G; mg/min) is equal to the sum of urinary excretion (U 3 V; mg/min) and extrarenal elimination (E; mg/min). Thus, GFR is related to the reciprocal of the plasma concentration of the marker (P), but also is influenced by its non-GFR determinants (G, TS, TR, and E). If the non-GFR determinants are known, GFR can be estimated from the plasma concentration. In the nonsteady state, it is more difficult to estimate GFR from the plasma concentration because the changes in plasma concentration lag behind changes in GFR and non-GFR determinants, including volume of distribution of the marker. Reproduced with permission from Levey et al.
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secondary to the immediate disappearance of the marker from the plasma into its volume of distribution (fast component) and to urinary excretion (slow component). Plasma clearance is best estimated by use of a two-compartment model that requires blood sampling early (usually two or three time points until 60 min) and late (one to three time points from 120 min onward). A widely used alternative method is to use a onecompartment model (the slow compartment only) with estimation of the fast compartment. Thus, plasma clearance of a substance depends not only on urinary and extrarenal clearance, but also on the time course for equilibration of the filtration marker between plasma and its volume of distribution. Plasma clearance measurements are popular because they avoid the need for timed urine collections, as described below; however, there are several limitations of this method. For markers that are eliminated by urinary and extrarenal routes, plasma clearance exceeds urinary clearance, leading to overestimation of GFR. Edematous conditions prolong the distribution from plasma to extracellular fluid and cause overestimation of GFR. If GFR is low, a longer interval for blood sampling is required to accurately measure the slow component, as long as 24 h for very low GFR; failure to extend the interval causes underestimation of GFR. 6 
Urinary clearance
Urinary clearance refers to the elimination of the marker from plasma by urinary excretion, and can be calculated as CL 5 U 3 V/P, where U is urinary concentration and V is the urinary flow rate (Figure 2b) . 5 Urinary excretion of a substance depends on the filtered load (the product of GFR 3 plasma concentration 3 sieving coefficient), tubular secretion (TS), and tubular reabsorption (TR). Markers that are filtered but not secreted or reabsorbed by the tubules are ideal filtration markers because their urinary clearance can be used as a measure of GFR. For markers that are filtered and secreted, urinary clearance exceeds GFR; and for markers that are filtered and reabsorbed, urinary clearance is less than GFR. 6 Measurement of urinary clearance requires a timed urine collection. The classic protocol of Homer Smith used a continuous intravenous infusion to achieve a steady state and bladder catheterization with multiple timed urine collections. Alternative protocols to assess urinary clearance have been validated, including bolus intravenous or subcutaneous administration rather than continuous intravenous infusion and spontaneous bladder emptying rather than bladder catheterization. Bolus administration of the marker results in declining plasma levels of the filtration markers during the clearance measurement, which may cause errors in determining the average plasma concentration. 6 Urinary clearance of endogenous filtration markers represents a special case in which infusion of the marker is not required. If the plasma level is constant during the interval of urine collection, urinary clearance can be computed from a timed urine collection and a single measurement blood sample. If the plasma level is not constant during the urine collection, as in acute kidney disease or when residual kidney function is assessed in patients undergoing intermittent dialysis, it is necessary to obtain additional blood samples during the urine collection to estimate the average plasma concentration. 6 
GFR ESTIMATION USING SERUM CONCENTRATIONS OF ENDOGENOUS FILTRATION MARKERS
GFR can be estimated from serum levels of endogenous filtration markers without requiring calculation of clearance (Figure 2c) . The plasma level of a solute (P) is related to its generation (G) by cells and dietary intake, urinary excretion (U 3 V), and extrarenal elimination (E). 5 Because urinary excretion represents the difference between generation (G) and extrarenal excretion (E), then GFR can be expressed as (G 1 TR -TS -E) / P. Thus, the level of GFR is related to the reciprocal of P, but it is also influenced by G, TR, TS, and E, collectively termed non-GFR determinants of the P. If the non-GFR determinants are known, GFR can be estimated from P. In clinical practice, the GFR determinants are generally not quantified, but, as described below, many factors are known to affect them. 5 Estimating equations for GFR are regression equations that estimate the level of mGFR from plasma concentrations of endogenous filtration markers and demographic and clinical variables as observed surrogates for the unmeasured non-GFR determinants. By definition, an estimating equation provides a more accurate estimate of mGFR than the plasma concentration alone, but understanding the potential sources of error is important for the interpretation of GFR estimates. Discrepancies between the true value for an individual and the average value for a study population in the relationship of the surrogates to the non-GFR determinants of the filtration marker leads to unavoidable differences between eGFR and mGFR. Other sources of error include measurement error in GFR or assays for endogenous filtration markers. In addition, most estimating equations for GFR were derived in the steady state, in which the plasma concentration is constant because the GFR and non-GFR determinants, including the volume of distribution of the marker, are constant; therefore, GFR estimates are more accurate in the steady state than in the nonsteady state. 5 In the nonsteady state, changes in GFR and the non-GFR determinants of the filtration marker lead to changes in its plasma concentration. Of particular importance is AKI, in which all may be changing. Hence, eGFR is less accurate in the nonsteady state than in the steady state; however, changes in eGFR do reflect the magnitude and direction of the change in true GFR. After a decrease in GFR, the lag in the rise in plasma concentration results in a lag in the decline in eGFR, and, thus, eGFR is higher than true GFR. Conversely, after an increase in GFR, the lag in the decline in plasma concentration result in a lag in the rise in eGFR, and, thus, eGFR is lower than true GFR. As the plasma concentration approaches the new steady state, eGFR approaches true GFR, allowing more accurate estimation.
Assessment of performance of GFR estimating equations in estimating mGFR requires evaluation in a different study population (validation population) than the one in which the equation was developed (development population). Accuracy of GFR estimates reflects "trueness" (absence of bias) and precision. Bias reflects a systematic difference between mGFR and eGFR due to systematic differences between the development and validation populations in the sources of error, whereas imprecision reflects random variation in the sources of error in the development or validation population. In general, differences among equations using the same filtration markers reflect differences in the variables included in the equations and the forms and coefficients of the variables. Differences among equations using different filtration markers also reflect differences among filtration markers in their biological variation, error in assay measurement, or non-GFR determinants. In principle, all these errors are likely to be larger (on the raw scale) at higher values for GFR although they may be more clinically significant at lower mGFR. 5 Considering the various sources of error, it is generally agreed upon that eGFR within 30% of an mGFR is satisfactory for clinical interpretation, and as a performance metric for accuracy, it is recommended that >90% of participants in the validation population have eGFR within 30% of the measured GFR (P 30 > 90%). 2 As shown later, GFR estimating equations developed in diverse populations have lesser bias at higher eGFRs than equations developed in CKD populations. However, even in the absence of bias, imprecision remains a barrier to exceeding this criterion for equations using only one filtration marker (either creatinine or cystatin C). In principle, the use of multiple filtration markers with noncorrelated non-GFR determinants can improve precision by reducing errors due to variation in non-GFR determinants of each marker. New equations that use both creatinine and cystatin C can achieve P 30 > 90%. 5 Bias or imprecision in eGFR could lead to errors in drug dosing, with consequent failure to achieve target therapeutic drug levels. Overdosing could lead to toxicity, whereas underdosing could reduce efficacy in treatment for the underlying condition. Performance of GFR estimating equations for drug dosing can be assessed by comparing drug levels or responses to therapy (toxicity or efficacy) after administration of a dose adjusted for eGFR vs. mGFR. Even if mGFR is not available, this approach allows comparison of eGFR equations. Unfortunately few studies are available using this approach.
Filtration markers
Characteristics of an ideal exogenous filtration marker, defined by Homer Smith, include that it is freely filtered by the glomeruli, excreted in the urine without tubular reabsorption or secretion, and has no effects on GFR. Solutes with molecular weight less than 20,000 Daltons and not bound to plasma proteins are freely filtered by the glomeruli and are candidate filtration markers. Inulin remains the "gold standard" for use in clearance measurements. Iothalamate, iohexol, ethylenediaminetetraacetic acid, and diethylenetriaminepentaacetic acid, often chelated to radioisotopes for ease of detection, are commonly used alternative exogenous filtration markers ( Table 1) . 3 Deviations from ideal behavior can be inferred from differences from inulin clearance during simultaneous clearance measurements.
A recent systematic review evaluated the accuracy of alternative methods in comparison with the classic procedure of the urinary clearance of inulin.
11 Preferred methods include urinary or plasma clearance of inulin, urinary or plasma clearance of iothalamate, urinary or plasma clearance of 51 Cr-EDTA, urinary or plasma clearance of iohexol, and urinary clearance of 99m Tc-DTPA. Of note, urinary creatinine clearance (CLcr) did not meet the criterion for accuracy due to large systematic bias and imprecision. Imaging methods are not preferred as they are less accurate than plasma and urinary clearance methods.
Currently identified endogenous filtration markers include metabolites (such as creatinine and urea) and low-molecular weight plasma proteins (such as cystatin C; Table 2 ).
5 Filtered metabolites are often excreted in the urine, but may undergo renal tubular reabsorption or secretion, which may be assessed by comparing their urinary clearances to urinary clearance of exogenous filtration markers. Extrarenal elimination of endogenous markers can be assessed by comparing their urinary excretion rate to their generation rate. By contrast, filtered plasma proteins are reabsorbed and degraded within the tubule with minimal appearance in the urine. As a result, it is more difficult to evaluate the renal tubular reabsorption, secretion, and extrarenal elimination of low-molecular weight plasma proteins than metabolites. 6 
GFR ESTIMATION USING CREATININE Metabolism and excretion
Creatinine was first identified in 1847 and proposed as a filtration marker in 1926. 8 It is a 113-Dalton end product of muscle catabolism. Advantages of creatinine include its ease of measurement and the low cost and widespread availability of assays ( Table 2) . 5 Disadvantages include the large number of conditions affecting its non-GFR determinants, leading to a wide range of GFR for a given serum creatinine level. For example, a serum creatinine level of 1.5 mg/dL (132 mmol/l) may correspond to a GFR from 20 to 90 mL/min/1.73 m 2 .
Creatinine is derived by the metabolism of phosphocreatine in muscle as well as from dietary meat intake or creatine supplements. Creatinine generation is proportional to muscle mass, which can be estimated from age, sex, race, and body size, but many other factors can affect creatinine generation. Creatinine is distributed in total body water, not protein bound, freely filtered across the glomerulus, and secreted by the tubules. Several medications, such as cimetidine, trimethoprim, and possibly fenofibrate, competitively inhibit creatinine secretion, leading to a rise in the serum creatinine concentration without an effect on GFR. In addition, creatinine is contained in intestinal secretions and can be degraded by bacteria; gastrointestinal elimination of creatinine is increased at higher levels of serum creatinine but can be reduced by changes in gut flora due to antibiotic use. Clinically, it can be difficult to distinguish a rise in serum creatinine concentration caused by inhibition of creatinine secretion or extrarenal elimination from a decline in GFR, especially in patients with low GFR. 6 Measured creatinine clearance (mCLcr)is usually assessed from the creatinine excretion in a 24-h urine collection and single measurement of serum creatinine in the steady state. Creatinine excretion rates vary with age, sex, and race, with mean levels of 20 to 25 mg/kg/day and 15 to 20 mg/kg/day in a complete collection in healthy young men and women, respectively. Deviations from estimated creatinine excretion (based on age, sex, weight, and other variables) can indicate errors in timing or completeness of urine collection, but cannot be relied upon due to wide variability in creatinine generation. 12 Measurement Jaff e described a method to detect creatinine in 1886 by reacting serum and urine with picrate under alkaline conditions, leading to the development of a red-orange color. 4 The alkaline-picrate assay was subsequently modified to minimize overestimation of serum creatinine due to "noncreatinine chromagens." These modifications were imperfect but it was convenient that the persistent underestimation of CLcr was now roughly equivalent to the clearance of creatinine due to tubular secretion, such that mCLcr approximated mGFR. Implementation of these modifications varied across clinical laboratories, even for the same instrument-method combination, leading to large variation among clinical laboratories. In a 2003 survey, the median bias of the instrument-method peer group assigned vs. true creatinine values was 0.12 mg/dL (10 lmol/L), with a range from -0.06 to 0.31 mg/dL (-5.3 to 27.4 lmol/L).
12 Variation of this magnitude would lead to important variation in assessment of GFR using creatinine as a filtration marker.
Variation in creatinine assays also led to inconsistency in development and implementation of drug dosing recommendations. 4 Pharmacokinetic studies performed using nonstandardized creatinine methods obtained results that were dependent upon the particular creatinine method used in a given study. Incorporating results from the pharmacokinetic studies into recommended drug dosages on the US Food and Drug Administration (FDA) drug labels led to inconsistent translation into clinical practice due to the variability among creatinine methods used in different laboratories. 4, 13 In 2005, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Kidney Disease Education Program (NKDEP), in collaboration with the National Institute of Standards and Technology (NIST) and College of American Pathologists (CAP), established a creatinine-standardization program to overcome these inconsistencies. In principle, creatinine standardization in clinical laboratories would enable more consistent implementation of dosing recommendations for all drugs. The effect of standardization varied among clinical laboratories, but on average has led to lower values for serum creatinine and higher values for eGFR using creatinine as a filtration marker than before standardization.
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Estimating equations
Many estimating equations have been developed using creatinine. The main limitations have been variation in serum creatinine assays and the variation in creatinine generation determined by muscle mass and diet. Despite standardization of serum creatinine assays and including age, sex, race, and body size as surrogates for creatinine generation, the equations have variable bias across populations and are imprecise. We focus on three equations that have been extensively validated and used in practicethe Cockcroft and Gault equation, because it was suggested by the FDA guidance to industry in 1998, 16 and the MDRD study and CKD-EPI equations because, as described below, they have been recommended by more recent clinical practice guidelines 6 
MDRD study equation
The MDRD study equation, developed in 1999, estimates GFR indexed for BSA (in mL/min/1.73 m 2 ) from age, sex, race (African American vs. white and other) and Scr. The study population included 1,628 men and women in the United States with a mean mGFR of 40 mL/min/1.73 m 2 . GFR was measured as the urinary clearance of iothalamate. Scr was measured using an alkaline picrate assay, which has now been calibrated to an isotopedilution mass spectrometry (IDMS)-traceable Scr assay, and the equation has been re-expressed for use with IDMS-traceable Scr assays. 5 A large study in a diverse study population showed that the 2006 MDRD study equation was found to be substantially more accurate compared to the Cockcroft-Gault equation (P 30 of 83% vs. 69%, respectively) because of lesser bias and greater precision. 17 A comparison of simulated dosing recommendations for 15 commonly used drugs in the same study population showed significantly higher concordance rates based on the MDRD study (removing indexing for BSA) than Cockcroft-Gault equations with mGFR (Table 3) . 5, 18 These results suggests that drug dosing recommendations for these drugs using the MDRD study would likely be more accurate than using the Cockcroft-Gault equation.
The main limitations of the MDRD study equation are: (1) it systematically underestimates mGFR at higher eGFR, so that numeric values cannot be reported for eGFR levels >60 mL/ min/1.73 m 2 ; and (2) the race variable includes coefficients only for African Americans vs. whites and others, so it may be more biased in populations of other races and ethnicities.
CKD-EPI equation
The CKD-EPI was formed in 2003 by the NIDDK to overcome the shortcomings of the 2006 MDRD study equation. The CKD-EPI assembled a pooled dataset of 12,150 participants from diverse studies in North America and Europe, including individuals with and without kidney disease and with diabetes, organ transplant recipients, and potential donors with mean mGFR of 68 mL/min/1.73 m 2 . In the development dataset, GFR was measured using urinary clearance of iothalamate. Serum samples were available for calibration to IDMS traceable reference materials and methods in all studies. Variables included in the final equation are the same as those in the MDRD study equation, but the forms of the variables and the coefficients differ. Diabetes status, organ transplant status, and weight were considered for inclusion but did not enhance equation performance. As with the MDRD study equation, the race variable includes coefficients only for African Americans vs. whites and others. 5 In comparison to the 2006 MDRD study equation, the CKD-EPI creatinine equation yields higher values at higher eGFR, for women, for whites and other races, and for ages younger than 70 years. Evaluation of the CKD-EPI vs. the MDRD study equation in the validation population showed improved accuracy (P 30 84.1% vs. 80.6%, respectively) and lesser bias, especially at eGFR >60 mL/min/1.73 m 2 , thus, it can be used to report a numeric value for eGFR throughout the range, including at levels 30 ranged from 59-95%. The P 30 was higher for the CKD-EPI equation than for the MDRD study equation in 10 studies and less accurate in 2 studies. Bias varied according to level of eGFR. Bias was smaller for the CKD-EPI equation than for the MDRD study equation at higher eGFRs, but larger at lower eGFRs; differences on the raw scale were larger at higher eGFRs and smaller and not clinically meaningful at lower eGFRs. The performance of both equations was not as good in regions outside North America, Europe, and Australia. Other equations and modifications using a local coefficient generally improved performance, but did not generalize to other studies. In general, the CKD-EPI creatinine equation with local modifications performed better than the MDRD study equation with local modifications. The authors concluded, "Neither the CKD-EPI nor the MDRD study equation is optimal for all populations and GFR ranges. Using a single equation for reporting requires a tradeoff to optimize performance at either higher or lower GFR ranges. A general practice and public health perspective favors the CKD-EPI equation." 19 Other equations have been reported since the development of the 2009 CKD-EPI creatinine equation, which perform as well or better than the CKD-EPI creatinine equation in some subgroups, but do not perform better than the CKD-EPI equation in a diverse population.
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GFR ESTIMATION USING CYSTATIN C Metabolism and excretion
Cystatin C was first identified in 1979 and proposed as a filtration marker in 1985. 8 It is a 122-amino acid protein with molecular weight of 13 kd ( Table 2) . 5 It is produced in all nucleated cells and is distributed in extracellular fluid. Approximately 99% of the filtered load of cystatin C is reabsorbed by the proximal tubular cells, where it is almost completely catabolized, with the remainder eliminated largely intact in the urine. Some evidence suggests the existence of tubular secretion as well as extrarenal elimination, the latter estimated at 15-21% of urinary clearance. Cystatin C is not affected by muscle mass or diet, and, thus, is more strongly correlated with mGFR than creatinine, and less strongly associated with age, sex, and race than creatinine. However, there are important clinical factors that seem to affect the non-GFR determinants of cystatin C. Smoking, inflammation, adiposity, thyroid diseases, certain malignant neoplasms, and use of glucocorticoids seem to be associated with higher cystatin C levels independent of mGFR.
Measurement
Several assays are available (all more expensive than those for creatinine). The International Federation of Clinical Chemists (IFCC) has developed a reference material for standardization of cystatin C, but international standardization of the assay is still in process, and important differences remain. 8, 24, 25 Estimating equations A number of equations to estimate GFR based on cystatin C (eGFRcys) or the combination of creatinine and cystatin C (eGFRcr-cys) have been developed. The 2012 CKD-EPI cystatin C equation and the 2012 CKD-EPI creatinine-cystatin C equation were developed and evaluated in a diverse population of 6,471 participants from a subset of the 2009 CKD-EPI creatinine equation development and validation dataset in which samples were available for measurement of serum cystatin C. The study population included participants with and without kidney disease and with diabetes, and potential organ donors with mean mGFR of 69 mL/min/1.73 m 2 . Studies that involved kidney transplant recipients were excluded. In the development dataset, GFR was measured using urinary clearance of iothalamate. Like the 2011 equations, the 2012 equations included age and sex in the cystatin C equation, and also include race in the combined creatininecystatin C equation. Diabetes status and weight were considered for inclusion but did not improve equation performance. 5 Evaluation in the validation population showed lesser bias of the 2012 CKD-EPI equations compared to the 2011 CKD-EPI equations. Comparison to the 2009 CKD-EPI equation showed similar accuracy of eGFRcys and eGFRcr-cys (P 30 of 87.2% and 85.9%, respectively), but higher accuracy of eGFRcr-cys (P 30 of 91.5%) due to improvement in precision rather than bias. Of interest, the average of eGFRcr and eGFRcys had similar accuracy as eGFRcr-cys. 5 There were few African Americans in the validation population, and a more recent study suggests small but significant differences in bias between African Americans and whites. 26 Evaluation of the 2012 CKD-EPI cystatin C equation in a Japanese population showed that it does not require modification by a local coefficient. 5 Studies using other equations have confirmed the findings that eGFRcr-cys is more precise than eGFRcr or eGFRcys and that eGFRcys may not require a local coefficient for racial or ethnic groups. 5 Other equations have been reported since the development of the CKD-EPI cystatin C and creatinine-cystatin C equations, which perform as well or better than the CKD-EPI cystatin C equation in some subgroups, but do not perform better than the CKD-EPI equation in a diverse population. 22, [26] [27] [28] These studies suggest a role for eGFRcys in conditions at the extremes of muscle mass or diet, and for races other than African American or white, and a role for eGFRcr-cys as a confirmatory test for decreased eGFRcr. In principle, eGFRcys or eGFRcr-cys could also be used for drug dosing. One study demonstrated substantially more frequent achievement of therapeutic vancomycin levels in intensive care unit patients with stable kidney function when eGFR was computed using the eGFRcr-cys with the CKD-EPI 2012 equation than the usual method based on eCLcr based on the Cockcroft-Gault equation (Table 4) . 26, 29 Clinical outcomes were similar using both methods. Another recent study called attention to differences between eGFRcr and eGFRcys in the frail elderly, who are prescribed a large number of drugs. 30 
CURRENT RECOMMENDATIONS Recommendations for clinical and laboratory practice
Kidney Disease Improving Global Outcomes. The Kidney Disease Improving Global Outcomes (KDIGO) 2012 CKD Guideline recommendations for GFR evaluation for adults in general clinical practice include initial testing using serum creatinine and a GFR estimating equation, and confirmatory testing using additional tests, such as serum cystatin C or a clearance measurement in specific circumstances in which eGFRcr is less accurate (Box 1).
3 For initial or confirmatory testing using serum creatinine or cystatin C, recommendations to clinicians include using an estimating equation rather than relying on the serum concentration alone, and to understanding clinical settings in which eGFRcr, eGFRcys, and eGFRcr-cys are less accurate. For confirmatory testing using a clearance measurement, the recommendations include using plasma or urinary clearance of an exogenous filtration marker rather than creatinine clearance. Recommendations to clinical laboratories included using assays for creatinine and cystatin C that are traceable to reference standards, and reporting eGFR using the CKD-EPI equations, or alternative equations if they are superior. The NKF-KDOQI commentary on the KDIGO guideline concurred with the recommendations for GFR evaluation, but recommended against widespread use of cystatin C because of concerns regarding incomplete understanding of its non-GFR determinants, higher costs, and incomplete standardization of assays. 31 National Kidney Disease Education Program. The NKDEP strongly encourages clinical laboratories to routinely estimate GFR in adults with an estimating equation using IDMS traceable serum creatinine and to report eGFR when serum creatinine is measured, when appropriate and feasible. 32 It describes the 2006 MDRD study and 2009 CKD-EPI creatinine equations as the two most widely used equations using IDMS traceable serum creatinine, and recommends the CKD-EPI equation for reporting numeric values >60 mL/min/1.73 m 2 . The 2013 CAP survey reported that virtually all global in vitro device manufacturers had transitioned their creatinine measurement procedures to be traceable to the IDMS reference measurement procedure, and that >85% of clinical laboratories in the United States were reporting eGFRcr using either the MDRD study or CKD-EPI equations whenever Scr was reported.
Recommendations for drug development and use
Kidney disease improving global outcomes. In 2010, KDIGO convened a Controversies Conference "Drug Prescribing in Kidney Disease: Initiative for Improved Dosing." 33 The conference, attended by 50 international experts, including representatives from the FDA and the EMA, was designed to explore understanding of drug disposition in patients with AKI and CKD, and to propose recommendations for the optimization of pharmacotherapy in the most common clinical practice settings. The conference generated recommendations for clinical practice, future research directions, and regulatory agencies to enhance the quality of pharmacokinetic and pharmacodynamic information available to clinicians. Regarding assessment of kidney function, the report states, "The pros and cons of the various GFR-estimating equations have been extensively reviewed and there is no compelling evidence of the superiority of any given method for drug dosing in all patient populations or clinical situations. Most of these studies have all compared the equations with each other in hypothetical simulations and not with actual drug clearance." It concludes that "Clinicians should use the method that provides the most accurate assessment of GFR." Recommendations on the assessment of kidney function are given in Box 2.
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Food and Drug Administration. In 2010, the FDA updated its "Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function." 34 The draft guidance revised the classification of impaired kidney function to be consistent with the KDIGO classification of CKD GFR categories, and considered eGFR using the MDRD study equation When reporting serum creatinine:
• We recommend that serum creatinine concentration be reported and rounded to the nearest whole number when expressed as standard international units (lmol/l) and rounded to the nearest 100th of a whole number when expressed as conventional units (mg/dL).
When reporting eGFRcr:
• We recommend that eGFRcr should be reported and rounded to the nearest whole number and relative to a body surface area of 1.73 m 2 in adults using the units mL/min/1.73 m 2 .
• We recommend eGFRcr levels <60 mL/min/1.73 m 2 should be reported as "decreased."
1.4.3.6: If cystatin C is measured, we suggest that health professionals (2C): Use a GFR estimating equation to derive GFR from serum cystatin C rather than relying on the serum cystatin C concentration alone. Understand clinical settings in which eGFRcys and eGFRcr-cys are less accurate.
1.4.3.7:
We recommend that clinical laboratories that measure cystatin C should (1B): Measure serum cystatin C using an assay with calibration traceable to the international standard reference material. Report eGFR from serum cystatin C in addition to the serum cystatin C concentration in adults and specify the equation used whenever reporting eGFRcys and eGFRcr-cys. Report eGFRcys and eGFRcr-cys in adults using the 2012 CKD-EPI cystatin C and 2012 CKD-EPI creatinine-cystatin C equations, respectively, or an alternative cystatin C-based GFR estimating equations if they have been shown to improve accuracy of GFR estimates compared to the 2012 CKD-EPI cystatin C and 2012 CKD-EPI creatinine-cystatin C equations.
When reporting serum cystatin C:
• We recommend reporting serum cystatin C concentration rounded to the nearest 100th of a whole number when expressed as conventional units (mg/l).
When reporting eGFRcys and eGFRcr-cys:
• We recommend that eGFRcys and eGFRcr-cys be reported and rounded to the nearest whole number and relative to a body surface area of 1.73m 2 in adults using the units mL/min/1.73 m 2 .
• We recommend eGFRcys and eGFRcr-cys levels <60 mL/min/1.73 m 2 should be reported as "decreased."
normal), 15-59 (moderately to severe), 15 without dialysis (end-stage), and requiring dialysis. The guidance recommends reporting pharmacokinetic studies using both eGFR and eCLcr. The guidance acknowledges that "In some circumstances, collection of 24-hour urine samples for measurement of creatinine clearance, or measurement of clearance of an exogenous filtration marker, may provide better estimates of GFR than the prediction equations." 34 The FDA guidance has not been updated since KDIGO and KDOQI have recommended that the CKD-EPI equation replace the MDRD study equation for routine clinical practice. However, the guidance noted that "In general, individuals with decreased eGFR in the range of 60 to 89 mL/min/1.73 m 2 without kidney damage are not at an increased risk for adverse outcomes from drugs that are renally excreted." 34 Because the CKD-EPI and MDRD study equations perform similarly at GFR below 60 mL/min/1.73 m 2 , it would be reasonable to use eGFR computed using the CKD-EPI equation or the MDRD study equation for pharmacokinetic studies and drug dosing.
European Medicines Agency. In 2014, the EMA updated its "Guideline on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Decreased Renal Function." 35 It recommended classification of levels of kidney function using the same categories as recommended by the FDA, but without indexing to BSA. The guidance acknowledges that "Methods for estimation of GFR (or other estimates of renal function such as creatinine clearance) in clinical practice vary between and within EU member states and over time. Therefore, it is recommended that a method accurately measuring GFR using an exogenous marker is used in pharmacokinetic studies in subjects with decreased renal function." 35 To evaluate dosing, the guidance recommends also estimating GFR using creatinine (using for example the CKD-EPI or MDRD study equations) or cystatin C or Box 1 Continued 1.4.3.8: We suggest measuring GFR using an exogenous filtration marker under circumstances in which more accurate ascertainment of GFR will impact on treatment decisions. (2B) CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; eGFRcr, estimated glomerular filtration rate from creatinine; eGFRcr-cys, estimated glomerular filtration rate from creatinine and cystatin C; eGFRcys, estimated glomerular filtration rate from cystatin C; GFR, glomerular filtration rate; IDMS, isotope-dilution mass spectrometry; KDIGO, Kidney Disease Improving Global Outcomes.
Reproduced from KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
estimating creatinine clearance (using, for example, the Cockcroft-Gault equation). "Thereby it may be confirmed whether the dosage recommendations developed based on measured GFR (e.g., which GFR cutoffs that should be used for dose adjustment) can be applied also using estimated GFR or estimated creatinine clearance. The cutoffs for dose adjustment should preferably be suitable regardless of which method for estimating renal function is used in clinical practice." 35 It recommends that when eGFR is provided in mL/min/1.73 m 2 , it should be converted to mL/min. National Kidney Disease Education Program. The NKDEP recommends use of either eGFR or eCLcr for drug dosing, and concluded that use of a single kidney function estimate to guide detection, evaluation, and management of CKD and drug dosing is likely to facilitate delivery of high-quality health care. 36 When using eGFR indexed for BSA for drug dosing in very large or very small patients, it recommends multiplying the reported eGFR by the estimated BSA/1.73 m 2 in order to obtain eGFR in units of mL/min. When prescribing drugs with narrow therapeutic indices, or for individuals in whom eGFR and eCLcr provide different estimates of kidney function, or for individuals in whom any estimates based on creatinine are likely to be inaccurate, it recommends considering assessment of GFR using alternative methods, such as mCLcr or mGFR using exogenous filtration markers.
CONCLUSIONS
There has been substantial progress during the past 20 years in the use of GFR assessment for detection, evaluation, and management of kidney disease. It is appropriate that these advances are now being applied to development, approval, and use of drugs (Box 3).
The eGFRcr is recommended as the initial test for GFR assessment for clinical use. In the steady state, eGFRcr may differ from mGFR in patients with deviations in non-GFR determinants or in racial-ethnic groups other than African American or white. In these cases, use of cystatin C, mGFR, or mCLcr as a confirmatory test is advised for more accurate assessment of GFR. In the nonsteady state, eGFR is less accurate and use of mGFR or mCLcr is recommended if it will influence clinical decision making. At extremes of body size, it is important to use eGFR and mGFR not indexed for BSA for drug dosing.
Although no estimating equation is optimal in all circumstances, eGFRcr using the CKD-EPI 2009 creatinine equation is recommended for clinical use, and there is no reason to believe that it would be less accurate for drug dosing than the CockcroftGault equation or other equations using Scr. It could be used for both kidney disease management and drug dosing to facilitate clinical practice. At this time, many clinical laboratories, including Quest and LabCorp report eGFRcr using the CKD-EPI equation, but others report eGFRcr using the 2006 MDRD study equation. Because the MDRD study and CKD-EPI equations give comparable GFR estimates for values <60 mL/min/1.73 m 2 , the MDRD study equation could be used for both kidney disease management and drug dosing until the clinical laboratories implement eGFRcr reporting using the CKD-EPI 2009 creatinine equation.
For new drugs, using the CKD-EPI 2009 equation in pharmacokinetic studies should allow more consistent development of dosing recommendations that can be easily applied in clinical Box 3 Our conclusions 1. GFR is generally the most useful index of kidney function. Clinicians should use the most accurate assessment of GFR available for kidney disease care and drug dosing. 2. The eGFRcr is often accurate enough for kidney disease care and drug dosing. In conditions in which eGFRcr is not accurate, eGFR based on cystatin C or a clearance measurement should be used. mGFR determined by clearance of exogenous filtration markers should be used rather than mCLcr, if available. 3. BSA adjustment of mGFR and eGFR is necessary for kidney disease care but not for drug dosing. mGFR and eGFR should not be indexed for drug dosing at extremes of BSA. 4. Accurate GFR estimation requires use of standardization of assays for endogenous filtration markers and expression of estimating equations for use with them. Virtually all clinical laboratories use standardized assays for creatinine, but cystatin C standardization is not yet optimal. 5. GFR should be estimated using the most accurate GFR estimating equation for each filtration marker (or combination), and use of a single equation for each filtration marker (or combination) for kidney disease care and drug dosing would facilitate clinical practice. 6. The CKD-EPI equations are the most accurate equations for eGFR using creatinine or cystatin C in diverse populations. Clinical laboratories should report eGFR using the CKD-EPI equations and clinicians should use them for kidney disease care and drug dosing. If the clinical laboratory reports eGFR using the MDRD study equation rather than the CKD-EPI equation, numeric estimates <60 mL/min/1.73 m 2 can be used for kidney disease care and drug dosing.
BSA, body surface area; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; eGFRcr, estimate glomerular filtration rate based on creatinine; GFR, glomerular filtration rate; mCLcr, modified creatinine clearance; mGFR, measured glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.
practice. For drugs previously approved using the Cockcroft-Gault equation before creatinine standardization, it is not likely that inconsistencies in the development of the dosing recommendations can be improved. 4 A single calibration factor cannot be derived to relate nonstandardized creatinine values in pharmacokinetic studies to standardized creatinine for use in the CockcroftGault equation, even if the instrument-method combination is known. If serum samples are available from the original pharmacokinetic studies, the results could be re-expressed using the 2009 CKD-EPI creatinine equation. Another possibility would be to repeat the pharmacokinetic studies. This may be worthwhile for highly toxic drugs with a narrow therapeutic window, but for most drugs the cost of repeating the studies would probably be prohibitive, especially if they are no longer covered by patents. 4 Epidemiologic studies may provide information for revisions to labels for some drugs. 37 In the absence of new information to revise the label for previously approved drugs, we would suggest drug dosing based on eGFRcr using the 2009 CKD-EPI equation is a reasonable alternative to continuing to use the CockcroftGault equation, which would be consistent with current recommendations and would facilitate clinical practice.
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